CHMP backs Raptor's Procysbi

EMA's CHMP recommended approval of Procysbi cysteamine bitartrate from Raptor Pharmaceutical Corp. (NASDAQ:RPTP) to treat nephropathic cystinosis. Raptor launched Procysbi in the U.S. earlier this month with an annual average per patient cost of $250,000. The product is a delayed-release formulation of a degradation product of the amino acid cysteine (see BioCentury, May 20). ...